

Claims

1. Non-human transgenic animal deficient in Gas6 function.
2. Non-human transgenic animal according to claim 1 in which said animal is Gas6⁺.
3. Non-human transgenic animal according to claim 1 or 2 in which said animal is a mouse.
4. Use of an animal according to claim 1-3 to study the role of Gas6 in endothelial activation.
5. Use of an inhibitor of the Gas6 function and/or an inhibitor of a Gas6 receptor for the manufacture of a medicament for the treatment of endothelial dysfunction.
6. Use according to claim 5 in which endothelial dysfunction results in a cardiovascular disorder such as, but not limited to, stroke, arterial restenosis, myocardial infarction.
7. Use according to claim 5 in which endothelial dysfunction results in abnormal angiogenesis.
8. Use according to claim 5-7 in which the Gas6 receptor is AXL, MER and/or RSE.
9. Use according to claim 8 in which the inhibitor is a soluble form of the AXL, MER or RSE receptor.
10. Use according to claim 5-8 in which the inhibitor is a Gas6 neutralising antibody.

Pety Caneher

P. V. G. de F. F. de F. F.

Estro

[Signature]